Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients

Wei Sheng Chen, Chun Yu Liu, Hui Ting Lee, Kelvin Tsai, Yi Chun Lin, Der Cherng Tarng, Chao Hung Ho, Hsiao Yi Lin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization), exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL) RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile range): 3.8 (2.9-4.8) g/dL versus 2.9 (2.0-3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate, preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially those with nonstainable iron marrow.

Original languageEnglish
Pages (from-to)469-477
Number of pages9
JournalClinical Rheumatology
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 1 2012
Externally publishedYes

Fingerprint

saccharated ferric oxide
Anemia
Rheumatoid Arthritis
Iron
Hemoglobins
Bone Marrow
Intravenous Administration

Keywords

  • Anemia
  • Iron compounds
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. / Chen, Wei Sheng; Liu, Chun Yu; Lee, Hui Ting; Tsai, Kelvin; Lin, Yi Chun; Tarng, Der Cherng; Ho, Chao Hung; Lin, Hsiao Yi.

In: Clinical Rheumatology, Vol. 31, No. 3, 01.03.2012, p. 469-477.

Research output: Contribution to journalArticle

Chen, Wei Sheng ; Liu, Chun Yu ; Lee, Hui Ting ; Tsai, Kelvin ; Lin, Yi Chun ; Tarng, Der Cherng ; Ho, Chao Hung ; Lin, Hsiao Yi. / Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. In: Clinical Rheumatology. 2012 ; Vol. 31, No. 3. pp. 469-477.
@article{3494239828b046288354f3513345b672,
title = "Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients",
abstract = "Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization), exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL) RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile range): 3.8 (2.9-4.8) g/dL versus 2.9 (2.0-3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate, preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially those with nonstainable iron marrow.",
keywords = "Anemia, Iron compounds, Rheumatoid arthritis",
author = "Chen, {Wei Sheng} and Liu, {Chun Yu} and Lee, {Hui Ting} and Kelvin Tsai and Lin, {Yi Chun} and Tarng, {Der Cherng} and Ho, {Chao Hung} and Lin, {Hsiao Yi}",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s10067-011-1885-0",
language = "English",
volume = "31",
pages = "469--477",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients

AU - Chen, Wei Sheng

AU - Liu, Chun Yu

AU - Lee, Hui Ting

AU - Tsai, Kelvin

AU - Lin, Yi Chun

AU - Tarng, Der Cherng

AU - Ho, Chao Hung

AU - Lin, Hsiao Yi

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization), exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL) RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile range): 3.8 (2.9-4.8) g/dL versus 2.9 (2.0-3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate, preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially those with nonstainable iron marrow.

AB - Anemia in rheumatoid arthritis (RA) is multifactorial. Iron deficiency, either definite or relative (defect in iron utilization), exists in RA patients with anemia. Intravenous iron therapy is indicated in severe and symptomatic cases or those with conditions precluding use of oral iron, but its safety and long-term efficacy have not been well-established. Forty severe anemic (hemoglobin < 9 g/dL) RA patients with or without demonstrable bone marrow iron stain were enrolled in this study. Fractionated administration of intravenous iron saccharate was undertaken and the median follow-up time was 1 year. All patients exhibited significant elevations of hemoglobin 3 months after treatment, which were more pronounced in the nonstainable iron marrow subjects {median (interquartile range): 3.8 (2.9-4.8) g/dL versus 2.9 (2.0-3.0) g/dL, p < 0.01}. Thereafter, hemoglobin remained at a plateau level that lasted during the observation period. Throughout the whole course, none of the cases exhibited side effects or flare up of disease activities. The use of intravenous iron saccharate, preferably administrated in a fractionated way, is effective in the correction of severe anemia in RA patients, especially those with nonstainable iron marrow.

KW - Anemia

KW - Iron compounds

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84859752017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859752017&partnerID=8YFLogxK

U2 - 10.1007/s10067-011-1885-0

DO - 10.1007/s10067-011-1885-0

M3 - Article

C2 - 22037665

AN - SCOPUS:84859752017

VL - 31

SP - 469

EP - 477

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 3

ER -